Status:
COMPLETED
Genetic Assessment of Early to Late Macular Degeneration Study
Lead Sponsor:
Henry Ferreyra
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
45+ years
Brief Summary
The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with e...
Detailed Description
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. To date, two major polymorphisms on the HTRA1 and CFH genes have been associated with AMD. Progression ...
Eligibility Criteria
Inclusion
- Subjects will be eligible if the following criteria are met:
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age \> 45 years
- Disease related considerations
- Subjects with a diagnosis of advanced AMD in one eye (either CNV or geographic atrophy) and soft confluent drusen in the study eye OR subjects with bilateral large soft drusen.
Exclusion
- Subjects with any other progressive retinal disease that may impair the physician's ability to assess the severity of AMD
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT01464710
Start Date
April 1 2008
End Date
January 1 2015
Last Update
June 21 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Diego
La Jolla, California, United States, 92093
2
California Retina Consultants
Santa Barbara, California, United States, 93108
3
Medical Center Ophthalmology Associates
San Antonio, Texas, United States, 78240